Companies
TissUse
German company TissUse developed the proprietary HUMIMIC technology, integrating built-in pneumatic micropumps for long-term (up to 28 days) 4-organ systemic co-culturing.
- Country
- Germany
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Certification | ISO 9001:2015 certified Quality Management System | biomed21.org · tissuse.com |
| Headquarters | Berlin, Germany | northdata.com |
| Production site | Berlin (Oudenarder Str. 16) and Spreenhagen, Germany | biomed21.org · northdata.com · tissuse.com |
| Capacity | In-house manufacturing of HUMIMIC platforms (Starter and AutoLab) and rapid prototyping for custom chip designs | biomed21.org · tissuse.com |
| Regulatory approval | No direct regulatory product approvals; active in qualifying assays with regulatory frameworks (e.g., FDA) for nonclinical testing medium confidence | biomed21.org |
Independent sources: biomed21.org · northdata.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Organoids & organ-on-chip | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.